BTK inhibitor
Ibrutinib (Specialist drug)
Brand names: Imbruvica
Adult dose
Dose: Specialist initiation only — refer to BNF/SmPC
Route: PO
Frequency: OD
Clinical pearls
- CLL, mantle cell lymphoma, Waldenström's macroglobulinaemia
Contraindications
- Concurrent strong CYP3A4 inducers/inhibitors without adjustment
Side effects
- Bleeding
- Atrial fibrillation
- Hypertension
- Infections (esp. opportunistic)
- Cytopenias
- Tumour lysis syndrome
Interactions
- Strong CYP3A4 modulators
- Anticoagulants/antiplatelets (bleeding)
Monitoring
- FBC
- BP
- ECG
- Bleeding
Reference: BNF; NICE TA429/TA491; SmPC; https://bnf.nice.org.uk/drugs/ibrutinib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Vancomycin Dosing Calculator · Drug Dosing
- Phenytoin Correction for Albumin / Renal Failure · Drug Dosing
- Local Anaesthetic Maximum Dose Calculator · Drug Dosing
- Tisdale Risk Score for QT Prolongation · Arrhythmia
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
Pathways
- Acute Myeloid Leukaemia Presentation · BSH; NICE — NG146
- Tumour Lysis Syndrome · Cairo-Bishop; BSH; NICE — Best Practice
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158